Acrux Ltd has released a press release.
Quarterly Activities / Appendix 4C Cashflow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Acrux
- Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
- Launch of prilocaine and lidocaine cream in United States
- Mutual Termination of Co-Development Agreement
- Chairman and CEO address to AGM
- Remaining balance of R&D Tax Incentive Rebate received
Later from Acrux
- Appendix 4D and Half Year Report
- 4th FDA ANDA approval received - Dapsone Gel, 5%
- Acruxs seventh generic dossier accepted by FDA for review
- Activities Statement and Appendix 4C
- Appendix 4E and FY23 Annual Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux